Cargando…

Serotonin re-uptake transporter gene polymorphisms are associated with imatinib-induced diarrhoea in chronic myeloid leukaemia patients

Tyrosine kinase inhibitors (TKIs), the treatment of choice for chronic myeloid leukaemia (CML), can cause lower gastrointestinal (GI) toxicity which is manifested as diarrhoea. The mechanisms are not fully understood. The enteroendocrine signalling compound, serotonin (5-HT), is important for regula...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davies, Andrea, Rodriguez-Vicente, Ana Eugenia, Austin, Gemma, Loaiza, Sandra, Foroni, Letizia, Clark, Richard E, Pirmohamed, Munir
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7242433/ https://www.ncbi.nlm.nih.gov/pubmed/32439979 http://dx.doi.org/10.1038/s41598-020-65350-0

Ejemplares similares

Molecular techniques for the personalised management of patients with chronic myeloid leukaemia
por: Alikian, Mary, et al.
Publicado: (2017)

A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease
por: Horne, G. A., et al.
Publicado: (2020)

Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment
por: Russo, D, et al.
Publicado: (2015)

The UK SPIRIT 1 trial in newly-diagnosed chronic myeloid leukaemia (CML)
por: Gallipoli, Paolo, et al.
Publicado: (2022)

Disease acceptance and adherence to imatinib in Taiwanese chronic myeloid leukaemia outpatients
por: Chen, Li-Chia, et al.
Publicado: (2013)

Rotating between ponatinib and imatinib temporarily increases the efficacy of imatinib as shown in a chronic myeloid leukaemia model
por: Lindström, H. Jonathan G., et al.
Publicado: (2022)

Imatinib adherence associated clinical outcomes of chronic myeloid leukaemia treatment in Taiwan
por: Chen, Teng-Chou, et al.
Publicado: (2013)

Modelling Predictors of Molecular Response to Frontline Imatinib for Patients with Chronic Myeloid Leukaemia
por: Banjar, Haneen, et al.
Publicado: (2017)

Cost–utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukaemia
por: Gordois, A, et al.
Publicado: (2003)

Hyperpigmentation of the hard palate mucosa in a patient with chronic myeloid leukaemia taking imatinib
por: Bombeccari, Gian Paolo, et al.
Publicado: (2017)

Rotavirus and Serotonin Cross-Talk in Diarrhoea
por: Bialowas, Sonja, et al.
Publicado: (2016)

Feasibility of treatment-free remission with generic imatinib: Results of generic imatinib-free trial-in-chronic myeloid leukaemia-chronic phase study
por: Goni, Deepak, et al.
Publicado: (2023)

Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia
por: Clark, Richard E., et al.
Publicado: (2021)

Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells
por: Halbach, Sebastian, et al.
Publicado: (2013)

Downregulation of the histone methyltransferase SETD2 promotes imatinib resistance in chronic myeloid leukaemia cells
por: Sheng, Yaru, et al.
Publicado: (2019)

A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia
por: Zhu, Jiewen, et al.
Publicado: (2013)

Intravitreal Bevacizumab and Triamcinolone for Treatment of Cystoid Macular Oedema Associated with Chronic Myeloid Leukaemia and Imatinib Therapy
por: Newcott, Eric K., et al.
Publicado: (2015)

Effectiveness of imatinib mesylate over etoposide in the treatment of sensitive and resistant chronic myeloid leukaemia cells in vitro
por: Husaini, Roslina, et al.
Publicado: (2017)

Molecular response to imatinib & its correlation with mRNA expression levels of imatinib influx & efflux transporters in patients with chronic myeloid leukaemia in chronic phase
por: Malhotra, Hemant, et al.
Publicado: (2015)

Serotonin involvement in okadaic acid-induced diarrhoea in vivo
por: Louzao, M. Carmen, et al.
Publicado: (2021)

ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia
por: Perrotti, D, et al.
Publicado: (2006)

Factors influencing long‐term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib
por: Brümmendorf, Tim H., et al.
Publicado: (2015)

Retraction: Carboxyamidotriazole-Orotate Inhibits the Growth of Imatinib-Resistant Chronic Myeloid Leukaemia Cells and Modulates Exosomes-Stimulated Angiogenesis
Publicado: (2019)

Impact of Fas/Fasl Gene Polymorphisms on Susceptibility Risk and Imatinib Mesylate Treatment Response in Chronic Myeloid Leukaemia Patients
por: Annuar, Aziati Azwari, et al.
Publicado: (2021)

Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors
por: Nteliopoulos, Georgios, et al.
Publicado: (2019)

Childhood leukaemia and lymphoma: African experience supports a role for environmental factors in leukaemogenesis
por: Williams, Christopher KO, et al.
Publicado: (2014)

Inhibition of IGF-IR tyrosine kinase induces apoptosis and cell cycle arrest in imatinib-resistant chronic myeloid leukaemia cells
por: Shi, Ping, et al.
Publicado: (2010)

Safety and efficacy of Vitamin D(3) supplementation with Imatinib in Chronic Phase- Chronic Myeloid Leukaemia: an Exploratory Randomized Controlled Trial
por: Bandyopadhyay, Arkapal, et al.
Publicado: (2023)

Recurrent histone mutations in T‐cell acute lymphoblastic leukaemia
por: Collord, Grace, et al.
Publicado: (2018)

Chemotherapy of the Myeloid Leukaemias
por: Stuart, John
Publicado: (1980)

Imatinib in Chronic Myeloid Leukemia: an Overview
por: Sacha, Tomasz
Publicado: (2014)

SUCCESSFUL TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER WITH ZIMELIDINE, A SEROTONIN RE-UPTAKE INHIBITOR
por: Prasad, Ashoka
Publicado: (1983)

Potentiated serotonin signaling in serotonin re‐uptake transporter knockout mice increases enterocyte mass and small intestinal absorptive function
por: Greig, Chasen J., et al.
Publicado: (2019)

Verapamil and diarrhoea in the carcinoid syndrome--clinical and experimental observations on serotonin release.
por: Ahlman, H., et al.
Publicado: (1986)

The Injury of Serotonin on Intestinal Epithelium Cell Renewal of Weaned Diarrhoea Mice
por: Dong, Y., et al.
Publicado: (2016)

A novel co-operative mechanism linking TGFβ and Lyn kinase activation to imatinib resistance in chronic myeloid leukaemia cells
por: Smith, Paul G., et al.
Publicado: (2012)

Early molecular response in East African Philadelphia chromosome-positive chronic myeloid leukaemia patients treated with Imatinib and barriers to access treatment
por: Henke, Oliver, et al.
Publicado: (2020)

Acute Myeloid Leukaemia in Its Niche: the Bone Marrow Microenvironment in Acute Myeloid Leukaemia
por: Ladikou, E. E., et al.
Publicado: (2020)

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial
por: Brümmendorf, Tim H, et al.
Publicado: (2015)

A Single Nucleotide Polymorphism in cBIM Is Associated with a Slower Achievement of Major Molecular Response in Chronic Myeloid Leukaemia Treated with Imatinib
por: Augis, Vanessa, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_sebejrhunda0jskhf36gjfkdfv